Retweeted NEJM (@NEJM): Phase 1 study testing vemurafenib/ipilimumab combo in metastatic melanoma w/ BRAF V600 stopped for hepatotoxicity. http://t.co/aH9HJKKbP1
via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/
via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/
No comments:
Post a Comment